Letybo®
letibotulinumtoxinA-wlbg
for Injection

ASK YOUR PROVIDER ABOUT **LETYBO®**

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using LETYBO® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received LETYBO® in the past.

Especially tell your healthcare provider if you have received any other botulinum toxin product in the last 4 months or any in the past, and exactly which product you received (such as MYOBLOC®, BOTOX®/BOTOX® COSMETIC, DYSPORT®, XEOMIN®, JEUVEAU®, or DAXXIFY®). LETYBO® may cause serious side effects, including allergic reactions (such as itching, rash, hives, wheezing, trouble breathing, or dizziness or feeling faint), heart problems (such as irregular heartbeat and heart attack), and eye problems (including dry eye, reduced blinking, and corneal problems). Tell your healthcare provider or get help right away if you experience a serious side effect. No serious side events of distant spread of toxin effect associated with dermatologic use of LETYBO® have been reported in clinical studies at the dose of 20 Units for glabellar (frown) lines. The most common side effect of LETYBO® was headache.

These are not all the possible side effects of LETYBO®. For more information, see the full Prescribing Information including Boxed Warning, and refer to the Medication Guide or talk with your doctor. To report side effects associated with LETYBO®, please call 1-877-390-2906. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

APPROVED USE

LETYBO® is a prescription medicine for adults that is injected into muscles to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).

REFERENCES:

1. Data on file. Hugel, Inc.; 2023. 2. Data on file. Total toxin sales 2010-2022. Hugel; February 23, 2023. 3. LETYBO® (letibotulinumtoxinA-wlbg) for injection, for intramuscular use. Prescribing Information. Chuncheon, Korea: Hugel, Inc; 4. Mueller DS, Prinz V, Adelglass J, Cox SE, Gold MH, et al. Efficacy and safety of letibotulinumtoxin A in the treatment of glabellar lines: a randomized, double-blind, multicenter, placebo-controlled phase 3 study. ASJ. 2022:42(6):677-688. doi:10.1093/asj/sjac019. 5. Cox SE, Kaufman-Janette J, Cohen JL, Gold M, Joseph J , et al. Letibotulinumtoxin A attenuates the psychological burden of glabellar lines and is associated with high subject satisfaction in phase 3 clinical trials. Dermatol Surg. 2024;50(6):535-54. doi:10.1097/DSS.0000000000004152.

Letybo®
letibotulinumtoxinA-wlbg
for Injection

— 31 —
MILLION+
SUCCESSFUL TREATMENTS
WORLDWIDE[2]

#1 FROWN LINE TREATMENT IN SOUTH KOREA,

the epicenter of beauty & skincare[1]

*LetibotulinumtoxinA, the active ingredient. Based on total reported revenue 2016-2024.

INDICATION

Letybo® is a prescription medicine for adults that is injected into muscles to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).

IMPORTANT SAFETY INFORMATION

Letybo® may cause serious side effects that can be life threatening. Call your healthcare provider or get medical help right away if you have any of these problems after treatment with Letybo®:

- **Problems swallowing, speaking, or breathing, due to weakening of associated muscles can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.**
- **Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms that include loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.**

Please see accompanying full Prescribing Information, including risk of SERIOUS SIDE EFFECTS, and Medication Guide, and additional Important Safety Information in this brochure.

CLEARLY SHOWN TO **IMPROVE THE LOOK** OF FROWN LINES

See **Real Results**

Before



After 4 Weeks



After 16 Weeks



Individual results may vary.

1,200+ people with moderate to severe frown lines were studied in 3 international studies.[3]

4 weeks after treatment, the **majority** of those injected with Letybo® (954 people) had either **none or mild frown lines.**

Do not receive LETYBO® if you are allergic to any of the ingredients in LETYBO® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as MYOBLOC® (rimabotulinumtoxinB), BOTOX® / BOTOX® COSMETIC (onabotulinumtoxinA), DYSPORT® (abobotulinumtoxinA), XEOMIN® (incobotulinumtoxinA), JEUVEAU® (prabotulinumtoxinA-xvfs), or DAXXIFY® (daxibotulinumtoxinA-lanm); or have a skin infection at the planned injection site. LETYBO® dosing units are not the same as, or comparable to, any other botulinum toxin product.

Tell your healthcare provider about all your medical conditions, including side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles, drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed.

DELIVERING ON THE **K-BEAUTY PHILOSOPHY**

of focus on innovation, radiance, and youthful appearance.

Clearly Letybo®

Quick Results with Letybo®

Letybo may start to work as early as **day 1** and typically **within 3 days**.

Consistent and **Enduring** Effects

may last up to **4 months** (16 weeks).

TRUSTED.
PROVEN.

- In 3 clinical studies, 954 people were treated with LETYBO®; 317 people received placebo (nonactive ingredients). *In 3 clinical studies, 954 people were treated with LETYBO®
- The majority of LETYBO®-treated people achieved at least a 2-grade improvement in frown lines and a frown line assessment of "mild" or "none" at 4 weeks.
- Percentage of people with "mild" or "no" frown lines:
  - Study 1 (LETYBO® n=266; placebo n=89): 79% LETYBO® vs 1% placebo (investigator assessment); 69% LETYBO® vs 0% placebo (self-assessment);
  - Study 2 (LETYBO® n=528; placebo n=175) 66% LETYBO® vs 1% placebo (investigator assessment); 55% LETYBO® vs 0% placebo (self-assessment);
  - Study 3 (LETYBO® n=160; placebo n=53) 75% LETYBO® vs 2% placebo (investigator assessment); 52% LETYBO® vs 2% placebo (self-assessment).[3]
- Please see Important Safety Information on back and LETYBO® full Prescribing Information including Boxed Warning and Medication Guide.